
Roughly half of patients on CGRP migraine treatments still don't see at least a 50% reduction in monthly migraine days. LauraChico, Ph.D. initiates on Mentari Therapeutics ($MTRI) at #OUTPERFORM ($33 PT). MTRI is developing therapies that target a complementary pathway, with initial data expected beginning in mid-2027. #EquityResearch #Biotech #Migraine #Investing













